NCT02640157View on ClinicalTrials.gov

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

February 28, 2017

Conditions
Chronic Hepatitis CHepatitis C VirusGenotype 3 Hepatitis C Virus
Interventions
DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

DRUG

Sofosbuvir

Tablet

DRUG

Daclatasvir

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY